Growth hormone treatment in Japan: past, present, and future
- PMID: 23330250
Growth hormone treatment in Japan: past, present, and future
Abstract
Growth hormone (GH) treatment was approved for growth hormone deficiency (GHD) in Japan in 1975. Since then, GH treatment has been approved for treating five other diseases with short stature. However, available data on adult height after long-term GH treatment is limited to patients with GHD and Turner syndrome. Although adult height of patients with GHD has improved with early diagnosis and early initiation of treatment, the adult height after long-term GH treatment is still not so satisfactory because the therapeutic dose used in Japan is smaller than that used in US and Europe. With early diagnosis, early high-dose treatment, and low-dose estrogen replacement therapy, both adult height and quality of life (QOL) of the patients with Turner syndrome have been improved.
Similar articles
-
Growth hormone: the expansion of available products and indications.Endocrinol Metab Clin North Am. 2009 Sep;38(3):587-611. doi: 10.1016/j.ecl.2009.06.006. Endocrinol Metab Clin North Am. 2009. PMID: 19717006
-
Quality of life and retrospective perception of the effect of growth hormone treatment in adult patients with childhood growth hormone deficiency.J Pediatr Endocrinol Metab. 2001;14 Suppl 5:1249-60; discussion 1261-2. J Pediatr Endocrinol Metab. 2001. PMID: 11964020
-
Effects of growth hormone on cognitive function.Horm Res. 2005;64 Suppl 3:89-94. doi: 10.1159/000089323. Epub 2006 Jan 20. Horm Res. 2005. PMID: 16439850 Review.
-
Clinical and humanistic aspects of growth hormone deficiency and growth-related disorders.Am J Manag Care. 2011 Dec;17 Suppl 18:eS4-10. Am J Manag Care. 2011. PMID: 22590765 Review.
-
Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).Growth Horm IGF Res. 2008 Aug;18(4):307-17. doi: 10.1016/j.ghir.2007.12.001. Epub 2008 Feb 20. Growth Horm IGF Res. 2008. PMID: 18282776 Clinical Trial.
Cited by
-
Factors Related to Treatment Non-Adherence Among Caregivers of Pediatric and Adolescent Growth Hormone Deficiency Patients in Japan.Patient Prefer Adherence. 2024 Mar 8;18:607-622. doi: 10.2147/PPA.S446649. eCollection 2024. Patient Prefer Adherence. 2024. PMID: 38476590 Free PMC article.
-
A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.J Clin Endocrinol Metab. 2016 Mar;101(3):1091-7. doi: 10.1210/jc.2015-3279. Epub 2015 Dec 16. J Clin Endocrinol Metab. 2016. PMID: 26672637 Free PMC article. Clinical Trial.
-
Perception of Adherence to Daily Human Growth Hormone Treatments Among Pediatric and Adolescent Patients in Japan: A Cross-Sectional Survey of Physicians and Caregivers.Patient Prefer Adherence. 2022 Nov 10;16:3081-3094. doi: 10.2147/PPA.S380871. eCollection 2022. Patient Prefer Adherence. 2022. PMID: 36387049 Free PMC article.
-
Patient preferences for growth hormone treatment in Japanese children.Pediatr Int. 2021 Oct;63(10):1185-1191. doi: 10.1111/ped.14760. Epub 2021 Aug 25. Pediatr Int. 2021. PMID: 33930225 Free PMC article.
-
Incidence of diabetes mellitus and neoplasia in Japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS).Clin Pediatr Endocrinol. 2017;26(4):229-241. doi: 10.1297/cpe.26.229. Epub 2017 Sep 28. Clin Pediatr Endocrinol. 2017. PMID: 29026272 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous